Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Despite the well-documented association between insulin resistance and cardiovascular disease, the key targets of insulin relevant to the development of cardiovascular disease are not known. Here, using non-biased profiling methods, we identify the enzyme flavin-containing monooxygenase 3 ( Fmo3 ) to be a target of insulin. FMO3 produces trimethylamine N-oxide (TMAO), which has recently been suggested to promote atherosclerosis in mice and humans. We show that FMO3 is suppressed by insulin in vitro , increased in obese/insulin resistant male mice and increased in obese/insulin-resistant humans. Knockdown of FMO3 in insulin-resistant mice suppresses FoxO1, a central node for metabolic control, and entirely prevents the development of hyperglycaemia, hyperlipidemia and atherosclerosis. Taken together, these data indicate that FMO3 is required for FoxO1 expression and the development of metabolic dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Insights into the mechanisms through which the meta-organismal pathway responsible for TMAO production are associated with enhanced CVD risks have thus far focused on the involvement of TMAO and FMO3 in atherosclerotic plaque development, altered sterol and glucose metabolism, and changes in macrophage phenotype (Wang et al., 2011 ; Koeth et al., 2013; Miao et al., 2015 ; Shih et al., 2015; War”
From Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk (2016) · cites this paper as Miao et al., 2015
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Knockdown of FMO3 in LIRKO mice suppressed FoxO1 expression (and improved glucose tolerance) by upregulating sterol regulatory element binding protein 2 (SREBP2) (77).”
From Trimethylamine N -Oxide, the Microbiome, and Heart and Kidney Disease (2017) · cites this paper as [77]
In the citing paper
“suppression of the host enzyme, FMO3, through antisense oligonucleotide-based approach, results in reduction of both circulating TMAO levels and diet-enhanced atherosclerosis in animal models”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Miao et al., 2015
In the citing paper
“Taken together, these data suggest that FMO3, which is differentially regulated in male and female mice, is necessary but apparently not sufficient for the development of the diabetic phenotype.”
From Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target (2018) · cites this paper as [76]
In the citing paper
“downregulation or knock-out of FMO3 leads to decreased levels of TMAO and it is athero-protective in these models, whereas increased expression of FMO3 leads to pro-atherogenic lipid profiles (e.g., higher VLDL and LDL) [75,76].”
From Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target (2018) · cites this paper as [76]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
affy—analysis of Affymetrix GeneChip data at the probe level
Gautier, L., Cope, L., Bolstad, B. M., & Irizarry, R. A. (2004) · Bioinformatics · doi:10.1093/bioinformatics/btg405 · Cited by 5,218
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
Koeth, R. A., Wang, Z., Levison, B. S., Buffa, J. A., Org, E., Sheehy, B. T., Britt, E. B., Fu, X., Wu, Y., Li, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3145 · Cited by 4,386
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk
Tang, W. H. W., Wang, Z., Levison, B. S., Koeth, R. A., Britt, E. B., Fu, X., Wu, Y., & Hazen, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109400 · Cited by 3,400
Grundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698
The Metabolic Syndrome: Time for a Critical Appraisal
Kahn, R., Buse, J., Ferrannini, E., & Stern, M. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2289 · Cited by 2,378
Research works printed but not linked: 2
- Shih, D. M. et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J Lipid Res 56, 22–37 (2015) . · DOI · Paper page
- Roberts, L. D., Souza, A. L., Gerszten, R. E. & Clish, C. B. Curr. Protoc. Mol. Biol eds Frederick M. A.et al. Chapter 30, Unit 30 32 31-24 (2012) .
Cited by
Plovier, H., Everard, A., Druart, C., Depommier, C., Van Hul, M., Geurts, L., Chilloux, J., Ottman, N., Duparc, T., Lichtenstein, L., et al. (2017) · Nature Medicine · doi:10.1038/nm.4236 · Cited by 2,204
Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk
Zhu, W., Gregory, J. C., Org, E., Buffa, J. A., Gupta, N., Wang, Z., Li, L., Fu, X., Wu, Y., Mehrabian, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.011 · Cited by 1,968
“, 2013), further confirm the involvement of this metaorganismal pathway in both atherosclerosis development and regulation of whole body cholesterol and sterol metabolism (Miao et al., 2015; Shih et al., 2015; Warrier et al., 2015).”
InfluentialRole of gut microbiota in type 2 diabetes pathophysiology
Gurung, M., Li, Z., You, H., Rodrigues, R., Jump, D. B., Morgun, A., & Shulzhenko, N. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.11.051 · Cited by 1,708
“Akkermansia muciniphila and Lactobacillus plantarum reduce the expression of hepatic flavin monooxygenase 3 (Fmo3) [37,93], a key enzyme of xenobiotic metabolism, whose knockdown has been found to prevent development of hyperglycemia and hyperlipidemia in insulin resistant mice [110].”
BackgroundWang, Z., Roberts, A. B., Buffa, J. A., Levison, B. S., Zhu, W., Org, E., Gu, X., Huang, Y., Zamanian-Daryoush, M., Culley, M. K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.055 · Cited by 1,317
“Toward that end, recent studies confirm that suppression of the host enzyme, FMO3, through an antisense oligonucleotide-based approach, results in the reduction of both circulating TMAO levels and diet-enhanced atherosclerosis in animal models (Miao et al., 2015; Shih et al., 2015).”
BackgroundDietary lipids, gut microbiota and lipid metabolism
Schoeler, M., & Caesar, R. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09512-0 · Cited by 1,163
Metadata
- Authors
- Miao, J., Ling, A. V., Manthena, P. V., Gearing, M. E., Graham, M. J., Crooke, R. M., Croce, K. J., Esquejo, R. M., Clish, C. B., Morbid Obesity Study Group, Torrecilla, E., Vázquez, G. F., Rubio, M. A., Cabrerizo, L., Barabash, A., Pernaute, A. S., Torres, A. J., Vicent, D., & Biddinger, S. B.
- Affiliations
- Boston Children's Hospital (US)
- Ionis Pharmaceuticals (United States) (US)
- Brigham and Women's Hospital (US)
- Sanford Burnham Prebys Medical Discovery Institute (US)
- Broad Institute (US)
- Carlos III Hospital (ES)
- Hospital Clínico San Carlos (ES)
- Universidad Complutense de Madrid (ES)
- Corresponding author
- Biddinger, Sudha B.
- ORCID
- Venue
- Nature Communications
- Published
- 2015-04-07
- Volume
- 6
- Issue
- 1
- Pages
- 6498-6498
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4391288
- OpenAlex
- W2094278898
- Cited by
- 368
- References
- 58
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 26 · 2023: 35 · 2022: 41 · 2021: 40 · 2020: 44 · 2019: 30 · 2018: 33 · 2017: 29 · 2016: 35 · 2015: 9
- FWCI
- 30.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- American Heart Association
- Brigham and Women's Hospital
- Wake Forest University
- Broad Institute
- Institut National de la Santé et de la Recherche Médicale
- Sociedad de Endocrinología, Nutrición y Diabetes de la Comunidad de Madrid
- National Heart, Lung, and Blood Institute (R01HL048044, HL48044, HL109650, R01HL109650)
- National Institute of Diabetes and Digestive and Kidney Diseases (L40 DK065607, K99DK100539, DK-100539, R00DK100539)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- FMO3, insulin resistance, diabetes-associated atherosclerosis, trimethylamine N-oxide, FOXO1, obesity, hyperglycemia, hyperlipidemia, metabolic dysfunction, insulin signaling
- MeSH terms
- Forkhead Box Protein O1, Animals, Diabetes Mellitus, Type 2, Humans, Hyperglycemia, Hyperlipidemias, Hypoglycemic Agents, Insulin, Insulin Resistance, Cholesterol, HDL, Cholesterol, LDL, Liver, Male, Obesity, Oxygenases, RNA, Messenger, Triglycerides, Blotting, Western, Rats, Sprague-Dawley, Gene Expression Profiling, Hepatocytes, Atherosclerosis, Mice, Rats, Forkhead Transcription Factors, Gene Knockdown Techniques, Real-Time Polymerase Chain Reaction, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. https://app.cochat.ai/papers/10.1038/ncomms7498
- The paper
- Miao, J., Ling, A. V., Manthena, P. V., Gearing, M. E., Graham, M. J., Crooke, R. M., Croce, K. J., Esquejo, R. M., Clish, C. B., Morbid Obesity Study Group, Torrecilla, E., Vázquez, G. F., Rubio, M. A., Cabrerizo, L., Barabash, A., Pernaute, A. S., Torres, A. J., Vicent, D., & Biddinger, S. B. (2015). Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nature Communications. https://doi.org/10.1038/ncomms7498
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.